StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)

Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –

Jazz Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Jazz Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $425.96M. For fiscal 2025 it was -$430.24M, down 160.0% from the year before. The highest annual figure on record is $716.63M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$430.24M-160.0%
FY2024Dec 31, 2024$716.63M+23.9%
FY2023Dec 31, 2023$578.58M–
FY2022Dec 31, 2022-$65.53M-138.5%
FY2021Dec 31, 2021$170.28M-55.0%
FY2020Dec 31, 2020$378.07M-29.0%
FY2019Dec 31, 2019$532.37M-13.4%
FY2018Dec 31, 2018$614.84M+16.3%
FY2017Dec 31, 2017$528.84M-10.6%
FY2016Dec 31, 2016$591.65M+16.4%
FY2015Dec 31, 2015$508.22M+159.8%
FY2014Dec 31, 2014$195.59M-42.5%
FY2013Dec 31, 2013$340.31M+72.0%
FY2012Dec 31, 2012$197.84M+54.8%
FY2011Dec 31, 2011$127.83M+121.2%
FY2010Dec 31, 2010$57.79M+262.8%
FY2009Dec 31, 2009$15.93M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$413.40M-819.0%
Q2 FY2026Jun 30, 2026$248.20M–
Q1 FY2026Mar 31, 2026$336.60M–
Q4 FY2025Dec 31, 2025$254.56M+33.4%
Q3 FY2025Sep 30, 2025$57.50M-77.9%
Q2 FY2025Jun 30, 2025-$686.40M-444.2%
Q1 FY2025Mar 31, 2025-$55.90M-184.4%
Q4 FY2024Dec 31, 2024$190.77M+55.7%
Q3 FY2024Sep 30, 2024$260.21M+50.9%
Q2 FY2024Jun 30, 2024$199.44M+26.5%
Q1 FY2024Mar 31, 2024$66.21M-47.5%
Q4 FY2023Dec 31, 2023$122.50M–
Q3 FY2023Sep 30, 2023$172.39M+596.2%
Q2 FY2023Jun 30, 2023$157.64M+84.3%
Q1 FY2023Mar 31, 2023$126.06M+44.0%
Q4 FY2022Dec 31, 2022-$263.39M-633.4%
Q3 FY2022Sep 30, 2022$24.76M-12.7%
Q2 FY2022Jun 30, 2022$85.55M–
Q1 FY2022Mar 31, 2022$87.55M-46.0%
Q4 FY2021Dec 31, 2021$49.38M-71.5%
Q3 FY2021Sep 30, 2021$28.37M-85.5%
Q2 FY2021Jun 30, 2021-$69.59M-135.1%
Q1 FY2021Mar 31, 2021$162.12M–
Q4 FY2020Dec 31, 2020$173.41M+183.1%
Q3 FY2020Sep 30, 2020$196.21M+47.4%
Q2 FY2020Jun 30, 2020$198.13M-3.0%
Q1 FY2020Mar 31, 2020-$189.67M-241.8%
Q4 FY2019Dec 31, 2019$61.25M-66.9%
Q3 FY2019Sep 30, 2019$133.10M-29.5%
Q2 FY2019Jun 30, 2019$204.28M+33.3%
Q1 FY2019Mar 31, 2019$133.74M+52.3%
Q4 FY2018Dec 31, 2018$185.06M+31.1%
Q3 FY2018Sep 30, 2018$188.78M+118.4%
Q2 FY2018Jun 30, 2018$153.20M-7.2%
Q1 FY2018Mar 31, 2018$87.81M-35.5%
Q4 FY2017Dec 31, 2017$141.21M-14.7%
Q3 FY2017Sep 30, 2017$86.45M–
Q2 FY2017Jun 30, 2017$165.04M–
Q1 FY2017Mar 31, 2017$136.14M–
Q4 FY2016Dec 31, 2016$165.50M–

More Jazz Pharmaceuticals figures

See a number that looks wrong?